NASDAQ
No price data available for this timeframe.
Iovance Biotherapeutics, Inc. (IOVA) has a price/fcf ratio of -2.90x as of Monday, May 25, 2026. This represents a 53.85% increase compared to its 12-month average of -6.29x. The price-to-free-cash-flow ratio measures a stock's price relative to its free cash flow per share, reflecting how efficiently a company generates cash.